Diabetic retinopathy (DRET) triggers vision loss in adults, however, little therapeutic options are existing. Memantine is an anti-Alzheimer drug that antagonizes the activity of glutamate at N-methyl-D-aspartate (NMDA) receptors. Glutamate and thioredoxin-interacting protein (TXNIP) are known to be overexpressed in diabetic retinas and can produce activation of NOD-like receptor protein 3 (NLRP3) with subsequent secretion of interlukin-1β. This study repurposed memantine for its neuroprotective effect in experimental DRET and tested its impact on ROS/TXNIP/NLRP3. In addition, KEGG pathway database and STRING database identified the protein-protein interaction between glutamate receptors and TXNIP/NLRP3. Male Swiss albino mice received alloxan (180 mg/kg) to induce DRET. After 9 weeks, we divided the mice into groups: (a) saline, (ii) DRET, (iii and iv) DRET + oral memantine (5 or 10 mg per kg) for 28 days. Then, mice were euthanized, and eyeballs were removed. Retinal samples were utilized for biochemical, histopathological, and electron microscopy studies. Retinal levels of glutamate, TXNIP, NLRP3 and interlukin-1β were estimated using ELISA technique as well as retinal malondialdehyde. Histopathological and ultrastructural examination demonstrated that oral memantine attenuated vacuolization and restored normal retinal cell layers. Moreover, memantine reduced TXNIP, NLRP3, interleukin-1β and MDA concentrations. These results provide evidence demonstrating memantine' efficacy in alleviating DRET via suppressing reactive oxygen species/TXNIP/NLRP3 signaling cascade. Therefore, memantine might serve as a potential therapy for retinopathy after adequate clinical research.
Nanostructured lipid carriers (NLCs) have been proven to significantly improve the bioavailability and efficacy of many drugs; however, they still have many limitations. These limitations could hinder their potential for enhancing the bioavailability of poorly water-soluble drugs and, therefore, require further amendments. From this perspective, we have investigated how the chitosanization and PEGylation of NLCs affected their ability to function as a delivery system for apixaban (APX). These surface modifications could enhance the ability of NLCs to improve the bioavailability and pharmacodynamic activity of the loaded drug. In vitro and in vivo studies were carried out to examine APX-loaded NLCs, chitosan-modified NLCs, and PEGylated NLCs. The three nanoarchitectures displayed a Higuchi-diffusion release pattern in vitro, in addition to having their vesicular outline proven via electron microscopy. PEGylated and chitosanized NLCs retained good stability over 3 months, versus the nonPEGylated and nonchitosanized NLCs. Interestingly, APX-loaded chitosan-modified NLCs displayed better stability than the APX-loaded PEGylated NLCs, in terms of mean vesicle size after 90 days. On the other hand, the absorption profile of APX (AUC0-inf) in rats pretreated with APX-loaded PEGylated NLCs (108.59 µg·mL−1·h−1) was significantly higher than the AUC0-inf of APX in rats pretreated with APX-loaded chitosan-modified NLCs (93.397 µg·mL−1·h−1), and both were also significantly higher than AUC0-inf of APX-Loaded NLCs (55.435 µg·mL−1·h−1). Chitosan-coated NLCs enhanced APX anticoagulant activity with increased prothrombin time and activated partial thromboplastin time by 1.6- and 1.55-folds, respectively, compared to unmodified NLCs, and by 1.23- and 1.37-folds, respectively, compared to PEGylated NLCs. The PEGylation and chitosanization of NLCs enhanced the bioavailability and anticoagulant activity of APX over the nonmodified NLCs; this highlighted the importance of both approaches.
Attention deficit hyperactivity disorder (ADHD) manifests as poor attention, hyperactivity, as well as impulsive behaviors. Hesperetin (HSP) is a citrus flavanone with strong antioxidant and anti-inflammatory activities. The present study aimed to test hesperetin efficacy in alleviating experimental ADHD in mice and its influence on hippocampal neuron integrity and sirtuin 1 (SIRT1) signaling. An in silico study was performed to test the related proteins. Groups of mice were assigned as control, ADHD model, ADHD/HSP (25 mg/kg), and ADHD/HSP (50 mg/kg). ADHD was induced by feeding with monosodium glutamate (0.4 g/kg, for 8 weeks) and assessed by measuring the motor and attentive behaviors (open filed test, Y-maze test, and marble burying test), histopathological examination of the whole brain tissues, and estimation of inflammatory markers. The in-silico results indicated the putative effects of hesperetin on ADHD by allowing the integration and analysis of large-scale genomic, transcriptomic, and proteomic data. The in vivo results showed that ADHD model mice displayed motor hyperactivity and poor attention in the behavioral tasks and shrank neurons at various hippocampal regions. Further, there was a decline in the mRNA expression and protein levels for SIRT1, the erythroid 2-related factor-2 (Nrf2), kelch like ECH associated protein 1 (Keap1) and hemeoxygenase-1 (OH-1) proteins. Treatment with HSP normalized the motor and attentive behaviors, prevented hippocampal neuron shrinkage, and upregulated SIRT1/Nrf2/Keap1/OH-1 proteins. Taken together, HSP mainly acts by its antioxidant potential. However, therapeutic interventions with hesperetin or a hesperetin-rich diet can be suggested as a complementary treatment in ADHD patients but cannot be suggested as an ADHD treatment per se as it is a heterogeneous and complex disease.
Toxoplasma gondii is a globally prevalent zoonotic parasite with major public health and veterinary impacts. In Egypt, One Health data on its distribution among blood donors and livestock are limited. This multicentric cross-sectional study aimed to determine the seroprevalence of Toxoplasma gondii among asymptomatic blood donors and livestock across six different Egyptian governorates and to identify the associated risk factors. Serum samples of 2000 asymptomatic blood donors and 500 animals (cattle and buffaloes) were tested for anti-Toxoplasma gondii IgG and IgM antibodies using ELISA. Sociodemographic and behavioral data were collected using a structured questionnaire. Overall IgG seroprevalence in blood donors was 41.8%, with IgM seropositivity at 2.1%. Significant regional variation was observed (p < 0.001), ranging from 66.5% in Alexandria to 16% in Cairo. The most significant risk factors were consumption of undercooked meat, contact with cats, and engagement in agricultural activities (p < 0.001). Among livestock, IgG and IgM seroprevalence were 7.2% and 5.2%, respectively, indicating active parasite circulation. The presence of seropositivity among apparently healthy donors raises concerns regarding transfusion safety. These findings highlight substantial and regionally heterogeneous Toxoplasma gondii exposure in Egypt. A One Health approach integrating public health education, food safety measures, and targeted screening of high-risk populations and animals is essential to reduce disease burden.
28 November 2024 in Suez Canal University Medical Journal
Background:Diabetic nephropathy is considered a main microvascular complication of diabetes mellitus (DM) that results in chronic renal failure. Fatty acid-binding protein 1 (FABP1) is expressed in renal proximal tubule cells and released into urine as a result of hypoxia triggered by decreased peritubular capillary blood flow, consequently urinary FABP1 is seen as a hopeful indicator for monitoring tubulointerstitial injury. There is increasing evidence that FABP1 plays a role in the development and progression of chronic kidney disease. Aim: This study aimed to assess the correlation of circulating plasma FABP1 level as well as its urinary level to nephropathy in patients with type 2 diabetes mellitus.Methods: Ninety patients were recruited, divided into 3 groups. They were investigated for glycemic and renal biomarkers, then FABP1 concentration was measured in their serum and urine samples. Bioinformatic analysis was done to explore the relation between FABP1 and DN. Results: The presence of DN was associated with increase in both serum and urinary FABP1. A serum FABP1 concentration of >243 ng/L was associated with DN, with a sensitivity of 93% and specificity of 90%, while urinary FABP1 concentration of >155.67 ng/L was associated with DN, with a sensitivity of 90% and specificity of 73%. Bioinformatic analysis revealed interactions between FABP1 and other kidney markers. Conclusion: This study proved that serum and urinary levels of FABP1 were significantly higher in the DN group than the normo-albuminuric groups reflecting the progression of the disease, thus they can be used as diagnostic biomarkers with significant sensitivity and specificity.